Inspire Medical Systems (INSP)

Executive Summary

Inspire Medical Systems is a commercial-stage medical device company focused on treating obstructive sleep apnea (OSA) with its innovative Inspire therapy, the only FDA-approved implantable neurostimulation system that provides a mask-free alternative to CPAP. The device stimulates the hypoglossal nerve to maintain airway patency during sleep, offering a solution for the approximately 30% of OSA patients who cannot tolerate or benefit from CPAP. Since its initial FDA approval in 2014, Inspire has gained significant market traction, with over 100,000 patients implanted and a growing base of trained implanting physicians. The company operates primarily in the United States and has expanded into select European markets, benefiting from strong clinical evidence and favorable reimbursement coverage from Medicare and many commercial insurers. Inspire Medical Systems has demonstrated robust revenue growth, with 2025 revenues exceeding $750 million, driven by expanding adoption and increasing patient awareness. The company's total addressable market in the US alone is estimated at over 10 million patients, providing substantial long-term growth potential. Despite competitive pressures from alternative therapies like hypoglossal nerve stimulation devices from other firms and emerging pharmaceuticals, Inspire's first-mover advantage, established clinical data, and strong physician training programs create significant barriers to entry. With a market capitalization of approximately $1.2 billion, the company appears undervalued relative to its growth trajectory and market opportunity.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for pediatric OSA indication65% success
• Q4 2026Expansion into Japan following PMDA submission70% success
• Q2 2026Positive 12-month outcomes from post-market study85% success